CIK 0001626971
- Non-accelerated filer
- Smaller reporting company
Corvus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- CRVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464670809
- Phone
- +1 650-900-4520
- Business address
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market buy President and CEO bought 15,008 shares at an average $3.00 ($45,029)
- 4 Open-market buy Director bought 142,656 shares at $3.51 ($500,723)
- 4 Open-market buy Director bought 142,656 shares at $3.51 ($500,723)
- 4 Open-market buy President and CEO bought 7,500 shares at an average $3.56 ($26,725)
- 4 Open-market sale 10% owner sold 1,492,956 shares at an average $4.07 ($6,077,845)
- 4 Open-market buy Director bought 657,344 shares at an average $3.72 ($2,444,065)
- 4 Open-market buy Director bought 657,344 shares at an average $3.72 ($2,444,065)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President and CEO bought 12,000 shares at an average $3.41 ($40,874)
- 4 Open-market buy President and CEO bought 15,212 shares at an average $3.49 ($53,039)
- 4 Open-market buy Chief Financial Officer bought 25,500 shares at an average $3.49 ($88,980)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
Page 8 of 13 · 252 filings